Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zofenopril + hydrochlorothiazide versus irbesartan + hydrochlorothiazide in essential hypertension uncontrolled on prior monotherapy
2008-007681-30Phase 3Completed
- Sponsor
- Istituto Lusofarmaco
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of zofenopril, hydrochlorothiazide and irbesartan in essential hypertension (2 arms), sponsored by Istituto Lusofarmaco. Primary endpoint: Blood pressure responder rate at 18 weeks. Started Mar 2009; status: completed.
02
Drugs
zofenoprilhydrochlorothiazideirbesartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2008-007681-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007681-30.